Abivax文件的IPO融资乙肝疫苗的临床试验，HIV病毒

StephenW

Abivax files for IPO to finance trials of HepB vaccine, HIV antiviral
May 21, 2015 | By Nick Paul Taylor


Abivax has filed the paperwork for an IPO in Paris. The listing is intended to give Abivax the cash to fund mid- to late-phase trials of its two lead candidates, a therapeutic vaccine against hepatitis B and a small-molecule inhibitor of HIV replication.


The hepatitis B vaccine, ABX203, is the more advanced of the two candidates. Abivax acquired the vaccine from Cuba's Centre for Genetic Engineering and Biotechnology, the R&D institute at the heart of the country's well-regarded biotech sector. Paris, France-based Abivax is enrolling people into a Phase IIb/III across Australia, New Zealand and the rest of the Asia-Pacific region in an attempt to show the vaccine can control the viral load of hepatitis B patients for longer than is possible using current treatments. The trial began in December.

If the trial is a success, Abivax plans to sell ABX203 in Asia-Pacific and Africa through distributors and look for a biopharma partner to bring it to market in Europe. Abivax plans to apply a similar geographic split to its HIV antiviral, ABX464, for which it is seeking a biopharma partner to handle the U.S. and Europe. The asset emerged from Abivax's collaboration with a French government research institute in Montpellier and has advanced as far as Phase IIa. Data are due later this year, after which Abivax will decide whether to plough its IPO haul into a pair of Phase IIb studies.

The proposed Phase IIb trials are among the main factors motivating the IPO. Abivax has yet to set a firm fundraising target for the IPO, but its chairman, Philippe Pouletty, put the goal around the €50 million ($55 million) mark when talking to BioPharm Insight last month. At that time, Pouletty viewed an IPO as a fallback option in case post-Phase IIa partnering discussions about ABX464 failed to lead to an attractive offer by 2016. Wrapping up the IPO now means Abivax could enter licensing discussions knowing it has the cash to advance into Phase IIb without a partner.

- read the release

Related Article:
Paris-based biotech ABIVAX launches pivotal clinical study on hep B candidate in Asia

StephenW

Abivax文件的IPO融资乙肝疫苗的临床试验，HIV病毒
2015年5月21日|尼克·保罗·泰勒


Abivax已经申请的文书工作在巴黎首次公开招股。上市的目的是让Abivax现金来资助中期到它的两个领先的候选人，对乙肝和艾滋病毒复制的小分子抑制剂的治疗性疫苗后期阶段试验。


乙肝疫苗，ABX203，是更先进的两位候选人。 Abivax收购了古巴的中心疫苗遗传工程和生物技术，在全国广泛关注的生物技术部门的心脏的研发机构。巴黎，法国的Abivax被招收到的人遍布澳大利亚，新西兰和亚太地区的其余部分IIb / III期，试图显示疫苗可以控制乙肝患者的病毒载量长于可能使用目前的治疗。该试验于12月开始。

如果试验成功，Abivax计划通过分销商在亚太和非洲地区销售ABX203并寻找一个生物制药的合作伙伴把它推向欧洲市场。 Abivax计划相似的地理分割应用于其艾滋病毒的抗病毒，ABX464，为此它正在寻求合作伙伴生物制药，以处理美国和欧洲。资产摆脱Abivax的合作，在蒙彼利埃是法国政府研究机构，并尽可能IIa期提前。数据是在今年晚些时候到期，之后Abivax将决定是否犁其IPO牵引成一对IIb期研究。

所提出的IIb期临床试验都属于激励在IPO的主要因素。 Abivax还没有设定一个坚定的目标筹款为IPO，但说话时的Insight生物制药上个月其董事长菲利普Pouletty，把周围的目标5000万€（55000000美元）标志。当时，Pouletty观看的IPO在情况后IIa期关于合作的讨论ABX464一个退而求其次的选择没有招致一个有吸引力的报价由2016年包装起来的IPO意味着现在Abivax可以进入许可的讨论知道它有现金前进进入IIb期没有一个合作伙伴。

- 阅读发行

相关文章：
总部位于巴黎的生物技术ABIVAX启动对乙肝候选人在亚洲举足轻重的临床研究

M15399835388

好事么

StephenW

回复 M15399835388 的帖子

股市筹钱

M15399835388

回复 StephenW 的帖子

晕死

StephenW

回复 M15399835388 的帖子

没钱就没有发展

9病成医

谢谢分享。

M15399835388

回复 StephenW 的帖子

话说可以请刘德华成立一个乙肝奖励基金，那样多好。他也是携带者啊

zgct

如果马云或马化腾说：在我们医药保健药品网上商城每构买100、元商品捐一元奖励英才乙肝药物研发！估计，可以在较短时间突破几百亿销售额，想自救的一亿乙人也或许可以随便供献百亿产值！齐参与或许好药就在转身间被发现

咬牙硬挺

感谢分享